Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000427 · ClinicalTrials.gov registry record · Phase 3
Effects of Parathyroid Hormone in Men With Osteoporosis
A Phase 3 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 81
- Enrollment target
NCT00000427: Completed Phase 3 study, sponsored by Massachusetts General Hospital.
NCT00000427 is a Phase 3 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 81 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000427, a Phase 3 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 81 participants
- Enrollment target
Study Summary
Alendronate is a drug that blocks or reduces bone loss, while parathyroid hormone (PTH) stimulates the formation of new bone. The purpose of this study is to compare the bone-building effects of PTH alone, alendronate alone, and both PTH and alendronate in men with osteoporosis over a two-and-a-half year period.
Interventions
- DRUG Alendronate
- DRUG Parathyroid hormone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 1999-09 |
| Est. Completion | 2005-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000427
The ClinicalTrials.gov registry entry for NCT00000427 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Alendronate is the first listed.
NCT00000427 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000427 about?
NCT00000427 is a clinical study titled "Effects of Parathyroid Hormone in Men With Osteoporosis". Alendronate is a drug that blocks or reduces bone loss, while parathyroid hormone (PTH) stimulates the formation of new bone. The purpose of this study is to compare the bone-building effects of PTH alone, alendronate alone, and both PTH and alendronate in men with osteoporosis over a two-and-a-half...
What is the current status of trial NCT00000427?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 81 participants. The study started on 1999-09. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00000427?
The interventions under investigation include: Alendronate (DRUG), Parathyroid hormone (DRUG).
Who is sponsoring clinical trial NCT00000427?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.